Daratumumab in multiple myeloma: an overview of 3 key trials

Niels van de Donk, MD, PhD from the University Medical Center, Amsterdam, Netherlands discusses three trials of daratumumab in multiple myeloma (MM). First, Dr van de Donk outlines the results of the Phase III POLLUX trial of daratumumab combined with lenalidomide and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) (NCT02076009). The trial was perfomed in the relapsed/refractory setting. There was an increase in response rate, complete response rate and further progression-free survival (PFS) was improved in the DRd vs the Rd arm. According to Dr van de Donk, this is the best triplet combination tested so far. He also discusses the side effect profile of daratumumab. The main toxicity, experienced by 50% of patients, was an infusion-related reaction, which is easily managed according to Dr van de Donk. Overall, the triplet combination was well-tolerated. He also discusses the MAIA trial of daratumumab plus lenalidomide and dexamethaonse vs lenalidomide and dexamethaonse in the upfront setting (NCT02252172), which is enrolling patients. Finally, Dr van de Donk outlines the results of the CASTOR trial of daratumumab plus bortezomib and dexamethasone vs bortezomib and dexamethasone (NCT02136134).
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Share this video